At the third edition of the symposium on controversial issues in the field of reproductive and perinatal medicine, Dr Llaneza highlights the role of anti-Müllerian hormone when personalising stimulation
Instituto Bernabeu participated in the third edition of the symposium on controversial issues in the field of reproductive and perinatal medicine which was held in Madrid in late January. Dr Ángela Llaneza, a specialist in reproductive medicine at the clinic in Madrid, participated in the event by giving a lecture entitled ‘Anti-Müllerian Hormone (AMH) and reproduction guidance’.
The gynaecologist highlighted that this hormone, which is produced by the ovaries, has served as an equivalent to a woman’s available ova for almost twenty years.
As the Instituto Bernabeu doctor pointed out, in the early days, anti-Müllerian hormone was limited to the field of reproductive medicine and nowadays, mainly as a result of developments in technology, it is available to patients from home and even beyond the boundaries of medicine.
“It is a very useful parameter that can be used during consultations to personalise patients’ stimulation treatment and adjust treatment expectations because a patient’s ovarian reserve tends to match her reaction to stimulation”, the gynaecologist points out. It is particularly important in the case of patients with poor ovarian reserve because this information serves as an early warning sign for experts who can then choose to use additional techniques to improve their patient's prognosis.